SNV1521-101
Research type
Research Study
Full title
A PHASE 1, OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SNV1521 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
IRAS ID
1011524
Contact name
Kevin O'Hayer
Contact email
Sponsor organisation
Synnovation Therapeutics, Inc.
Clinicaltrials.gov Identifier
Research summary
This research study involves receiving a new investigational drug referred to as SNV1521. This study is a Phase 1 study which means this is the first study in which humans will be taking the study drug. About 200 male and female participants aged 18 years and older with advancer cancer will take part in this study. The study will take place at up to 30 study centres in up to 7 countries including the United States, United Kingdom, Canada, France, Italy, Spain and Australia. The study is planned to last for up to 2 years. The study sponsor is Synnovation Therapeutics, Inc. who will be funding this clinical trial. This study will be made up of 3 parts:
• SNV1521 Dose Escalation: The purpose of the dose escalation portion of the study is to test the safety of the study drug when different dose levels are given to small numbers of study participants in order to find out what effects, good and/or bad, a given dose of study drug has on the type of cancer.
• SNV1521 Dose Expansion: The purpose of the dose expansion portion of the study is to give the study drug at safe doses identified from the dose escalation portion to a larger number of study participants so more information on the safety and effects, good and/or bad, the study drug has on the type of cancer can be collected.
• Combination Therapy Dose Escalation: The purpose of the dose escalation portion of the study is to test the safety of the study drug when different dose levels are given in combination with another anti-cancer to small numbers of study participants in order to find out what effects, good and/or bad, a given dose of study drug has on you and your type of cancer.REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
25/YH/0044
Date of REC Opinion
14 Apr 2025
REC opinion
Further Information Favourable Opinion